The Aporia
Casiano, L. (2026, November 20). EXCLUSIVE: Trump’s FDA nominee vows new abortion pill safety review after pressure from Sen Hawley. Fox News. https://www.foxnews.com/politics/exclusive-trumps-fda-nominee-vows-new-abortion-pill-safety-review-after-pressure-sen-hawley
Casiano, Louis. “EXCLUSIVE: Trump’s FDA nominee vows new abortion pill safety review after pressure from Sen Hawley.” Fox News, 20 Nov. 2026, https://www.foxnews.com/politics/exclusive-trumps-fda-nominee-vows-new-abortion-pill-safety-review-after-pressure-sen-hawley.
Casiano, Louis. “EXCLUSIVE: Trump’s FDA nominee vows new abortion pill safety review after pressure from Sen Hawley.” Fox News, November 20, 2026. https://www.foxnews.com/politics/exclusive-trumps-fda-nominee-vows-new-abortion-pill-safety-review-after-pressure-sen-hawley.
Dated from the outlet's own feed. Check the original for its byline.
Former FDA commissioner nominee Dr. Heidi Overton has committed to establishing a binding timeline and clear parameters for a safety study on the abortion medication mifepristone, according to the office of Sen. Josh Hawley, R-Mo., on November 20, 2026. Sen. Hawley, a member of the Senate Health, Education, Labor and Pensions (HELP) Committee, has been pressing federal health officials for accountability over the delayed assessment of mifepristone's safety. Overton, who was initially nominated by President Donald Trump in August 2026, stated in her Senate committee confirmation questionnaire that she would expect the FDA to make the scientific basis and results of the review public to the greatest extent permitted by law. The White House withdrew Overton's nomination a day before a Senate committee vote, though the reasons were not specified. Sen. Hawley expressed confidence that the FDA will uphold its commitments, emphasizing the importance of robust studies and reinstating safeguards on the abortion drug that were removed under President Biden's administration.